Trelagliptin Succinate NDA in Japan Captures Global Attention of Pharmaceutical World


Trelagliptin SuccinateRecently, the Trelagliptin Succinate NDA has captured pharmaceutical headlines as it was accepted by the Japanese Ministry of Health, Labour and Welfare. As a unique once weekly treatment for type 2 diabetes, Trelagliptin Succinate is an effectual dipeptidyl peptidase-IV inhibitor. As one of the few providers in the world of Trelagliptin Succinate, LGM Pharma offers this API product for research and development purposes. Takeda Pharmaceuticals, alongside Furiex Pharmaceuticals announced their excitement over a possible marketing of this much needed drug to fight type 2 diabetes in Japan. Trelagliptin Succinate not only offers patients an easy to adhere to treatment for regulating their glucose levels, but it also has proven in a multitude of studies to provide constant and consistent blood sugar control.

The global impact of type 2 diabetes is vast and daunting in nature, with the Worldwide Health Organization predicting type 2 diabetes to be the seventh leading cause of death by the year 2030. India, America and China are currently leading in the number of cases of type 2 diabetes, but other nations are following close behind. Japan, Brazil, Russia, Indonesia, Pakistan and Italy have all shown great increases of patients with type 2 diabetes, and the numbers are not expected to decline.

Clinical trials of Trelagliptin Succinate have proven to be efficacious, with Phase III studies having started in September of 2011. The Phase III trials focused on roughly 600 patients in Japan with type 2 diabetes, and followed these patients for a full year. Trelagliptin clearly offered greater viability as compared to both Sitagliptin Phosphate and a placebo, with the majority of patients who were administered Trelagliptin gleaning a significant decrease in their HbA(1c) levels. Trelagliptin Succinate is also thus far the only “gliptin” that is documented safe in terms of cardiovascular risks.

LGM Pharma supplies the API Trelagliptin Succinate CAS# 1029877-94-8 for research and development purposes.  Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: